Taysha Gene Therapies Inc’s recently made public that its 10% Owner Manning Paul B acquired Company’s shares for reported $0.16 million on Nov 17 ’23. In the deal valued at $1.63 per share,100,000 shares were bought. As a result of this transaction, Manning Paul B now holds 16,566,667 shares worth roughly $48.71 million.
Then, Alam Kamran sold 33,000 shares, generating $76,890 in total proceeds. Upon selling the shares at $2.33, the Chief Financial Officer now owns 258,042 shares.
Before that, Manning Paul B bought 16,466,667 shares. Taysha Gene Therapies Inc shares valued at $14,820,000 were divested by the 10% Owner at a price of $0.90 per share. As a result of the transaction, Manning Paul B now holds 16,466,667 shares, worth roughly $48.41 million.
Piper Sandler initiated its Taysha Gene Therapies Inc [TSHA] rating to an Overweight in a research note published on April 09, 2024; the price target was $9. A number of analysts have revised their coverage, including Jefferies’s analysts, who decreased its forecast for the stock in early February from “a Buy” to “a Hold”. Morgan Stanley also remained covering TSHA and has decreased its forecast on January 27, 2023 with a “an Equal-weight” recommendation from previously “an Overweight” rating. Goldman revised its rating on November 09, 2022. It rated TSHA as “a Neutral” which previously was an “a Buy”.
Price Performance Review of TSHA
On Friday, Taysha Gene Therapies Inc [NASDAQ:TSHA] saw its stock fall -8.70% to $2.94. Over the last five days, the stock has gained 9.70%. Taysha Gene Therapies Inc shares have risen nearly 66.10% since the year began. Nevertheless, the stocks have risen 335.23% over the past one year. While a 52-week high of $3.89 was reached on 03/01/24, a 52-week low of $0.50 was recorded on 01/19/24. SMA at 50 days reached $2.44, while 200 days put it at $2.00. A total of 1.68 million shares were traded, compared to the trading of 3.26 million shares in the previous session.
Levels Of Support And Resistance For TSHA Stock
The 24-hour chart illustrates a support level at 2.82, which if violated will result in even more drops to 2.70. On the upside, there is a resistance level at 3.17. A further resistance level may holdings at 3.40. The Relative Strength Index (RSI) on the 14-day chart is 55.32, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.19, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 59.39%. Stochastics %K at 60.00% indicates the stock is a holding.
The most recent change occurred on March 09, 2022 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $26 price target.
